New data shows 70% of newly documented BPC-157 users are men, as millions search for experimental peptides and laboratory experts warn against relying on “99% purity” claims
Interest in experimental peptides is surging both online and in documented real-world use, with new data revealing a dramatic increase in searches for the so-called “Wolverine Stack”.
New Google search analysis by Licensed Peptides shows searches for “Wolverine Stack” have increased 948% over the past year, reaching approximately 21,000 searches in the past month.
The term commonly refers to the combination of experimental peptides BPC-157 and TB-500, which has attracted significant attention online around claims relating to recovery and tissue repair.
Now, separate new research analysing 15.2 million medical records suggests interest is translating into documented real-world use.
Researchers at healthcare data company nference identified 1,039 patients with confirmed BPC-157 use between 2020 and 2026.
Newly documented users increased from just four in the first quarter of 2020 to 134 in the first quarter of 2026, an approximately 33-fold increase.
Men increasingly dominate that group.
The proportion of newly documented users who were male increased from 57% in 2020 to 70% in 2026, while the average age fell from 55 to 49.
TB-500, the second peptide commonly associated with the “Wolverine Stack”, was documented alongside BPC-157 in 12.9% of confirmed users.
The findings come as Licensed Peptides’ search analysis shows significant increases in interest across a much wider range of experimental peptides.
| Peptide | Monthly Google searches | Annual growth |
| Retatrutide | 2.8 million | +979% |
| BPC-157 | 456,000 | +572% |
| Semax | 251,000 | +549% |
| TB-500 | 199,000 | +876% |
| CJC-1295 | 176,000 | +1,041% |
| GHK-Cu Copper Peptide | 51,000 | +6,407% |
| Wolverine Stack | 21,000 | +948% |
Dr. Samuel Sarmiento, MD, MPH, MBA, spokesperson for Licensed Peptides, says the combination of search and medical-record data demonstrates how quickly experimental peptides are entering mainstream conversation.
He said:
“The numbers are striking because we’re now seeing two different signals moving in the same direction.
Searches for the Wolverine Stack have increased 948% in a year, while separate medical-record research has found newly documented BPC-157 users increased approximately 33-fold between 2020 and 2026.
That doesn’t tell us these compounds are safe or effective. What it tells us is that interest is growing considerably faster than many people probably realise.”
The ‘Wolverine Stack’ is not an approved treatment
Despite its growing popularity online, the “Wolverine Stack” is not the name of an FDA-approved treatment.
BPC-157 is not currently an FDA-approved drug, while the term “Wolverine Stack” is an informal name used online for combining BPC-157 with TB-500.
The new nference research does not establish whether BPC-157 is safe or effective.
The study was retrospective, relied on information contained within clinical notes and has been released as a preprint ahead of peer review.
Treatment outcomes were also inconsistently documented, while many patients were simultaneously using other substances.
Of the 1,039 confirmed BPC-157 users identified by researchers, 50.5% had documented use of at least one other therapeutic agent.
Dr. Sarmiento said:
“Calling something a ‘stack’ can make it sound like an established protocol. It isn’t.
Combining two experimental compounds doesn’t automatically mean the combination itself has been adequately studied.
The fact that 70% of newly documented users were male in 2026 is particularly relevant given how heavily these compounds are discussed in male fitness, recovery and performance communities.”
Search interest in BPC-157 itself is up 572%
The Wolverine Stack is only part of a much wider surge.
Licensed Peptides’ analysis found approximately 456,000 monthly searches for BPC-157, up 572% year on year.
TB-500 attracted approximately 199,000 monthly searches, increasing 876%.
CJC-1295 searches increased 1,041%, while GHK-Cu Copper Peptide recorded the largest percentage increase in the analysis at 6,407%.
Retatrutide generated the highest overall search volume at approximately 2.8 million searches per month, up 979% year on year.
Dr. Sarmiento said:
“The speed at which some of these search terms are growing shows how quickly peptides have moved outside specialist scientific conversations.
The concern is that as awareness increases, scientific terminology can easily be mistaken for evidence of safety.
‘Research grade’, ‘99% purity’ and even ‘Certificate of Analysis’ can all sound reassuring to someone unfamiliar with laboratory testing, but none of those phrases alone tells you everything about the quality of a product.”
Why ‘99% purity’ doesn’t tell the whole story
Licensed Peptides says one of the biggest misunderstandings surrounding research peptides relates to laboratory testing.
A stated purity percentage measures only one characteristic of a sample.
Dr. Sarmiento continued:
“People often assume a purity percentage tells the whole story. It doesn’t.
A product can return a high purity result while still leaving other important questions unanswered, including whether the compound’s identity has been independently confirmed and whether the quantity stated on the label is actually present.
For legitimate laboratory researchers, batch-specific documentation and transparent testing methods are far more useful than a headline purity percentage.”
According to Dr. Sarmiento, appropriate quality verification can assess:
- Identity of the peptide
- Quantity of peptide present
- Chemical purity
- Sterility
- Endotoxin levels
- Visual quality
The company says every batch it supplies undergoes a six-stage verification process before release for laboratory research, including HPLC purity analysis, mass spectrometry identity confirmation, endotoxin screening, sterility testing, content verification and visual inspection.
Regulators are also scrutinising the peptide market
The increase in interest comes as regulators continue to scrutinise unapproved peptide products.
Earlier this year, the UK’s Medicines and Healthcare products Regulatory Agency seized almost 2,000 doses of suspected illegal weight-loss medicines and peptide products during raids on two sites suspected of manufacturing and distributing unlicensed products.
In the United States, the FDA has also taken enforcement action involving companies marketing unapproved injectable peptide products.
At the same time, regulators are considering the future of some peptides within pharmacy compounding.
In July, the FDA’s Pharmacy Compounding Advisory Committee narrowly recommended that BPC-157-related bulk drug substances be included on the 503A Bulks List, despite FDA staff recommending against inclusion based on their assessment of the available evidence.
The committee voted 8-6, with one abstention.
The recommendation is advisory and does not mean BPC-157 has been approved by the FDA.
Dr. Sarmiento said:
“This is where the peptide conversation can become confusing very quickly.
An FDA-approved medicine, a product compounded by a licensed pharmacy and a research peptide supplied strictly for laboratory work operate within different regulatory contexts.
People shouldn’t interpret availability in one of those settings as approval for another.”
Researchers urged to look beyond the label
Licensed Peptides says growing mainstream attention makes transparency particularly important for legitimate researchers purchasing materials for laboratory use.
Dr. Sarmiento added:
“The biggest misconception is that a professional-looking vial automatically means the contents have been properly verified.
A poorly manufactured or mislabelled research product could contain less material than stated, more than expected, a different compound or contaminants introduced during manufacturing.
Researchers should look for batch-specific Certificates of Analysis, clear analytical methods, independent laboratory testing and transparent manufacturing and quality-control information.
Transparency shouldn’t be viewed as a marketing feature. Researchers need to know what they’re working with if their results are going to mean anything.”